Sangamo Therapeutics, Inc. (NASDAQ: SGMO) shares were unchanged at $3.65, as the company announced today that the U.S. Food and Drug Administration has granted orphan drug designation to SB-318, a genome editing product candidate for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare lysosomal storage disorder. Share volume totaled 574,000 compared to an all-day average of 939,000
